NephroGenex
Latest round
- Series A
Last raised
- Jun 2008
Total raised
- $29M
Investors
- 4
About NephroGenex
NephroGenex, Inc.NephroGenex, Inc. specializes in therapies for kidney diseases and is headquartered in the US.1 million shares at an exit share price of USD 12.NephroGenex, Inc. primarily focuses on the development and commercialization of innovative therapies aimed at treating kidney diseases, with a particular emphasis on diabetic nephropathy. Their lead product, PYRIDORIN® (pyridoxamine dihydrochloride), functions as a scavenger of oxidative chemistries that contribute to the pathogenesis of diabetic nephropathy and end-stage renal disease. By targeting these harmful chemistries, PYRIDORIN® aims to slow disease progression, as evidenced by positive outcomes in Phase 2 clinical studies. The company is currently enrolling participants in the pivotal Phase 3 PIONEER study to further evaluate the drug's efficacy.NephroGenex generates revenue through the development and potential commercialization of its lead product, PYRIDORIN®. The company's revenue model is structured around partnerships with pharmaceutical distributors and healthcare providers, facilitating the delivery of their therapies to end-users in clinical settings. As the company progresses through its clinical trials, successful outcomes may lead to pricing arrangements and licensing agreements with larger pharmaceutical entities. Following the successful completion of the Phase 3 PIONEER study, the company aims to seek regulatory approvals for its lead product and explore potential international markets.5 mn, which will support these initiatives and enhance strategic partnerships with healthcare institutions. NephroGenex is poised to venture into new territories following positive clinical trial results.
Who invested in NephroGenex
4 investors across 3 rounds
See all investors in NephroGenex
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NephroGenex
Who invested in NephroGenex?
NephroGenex has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NephroGenex raised?
NephroGenex has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did NephroGenex last raise money?
NephroGenex's most recent round on record is a Series A, in Jun 2008.
What does NephroGenex do?
NephroGenex is a pharmaceuticals company.
Where is NephroGenex headquartered?
NephroGenex is headquartered in US.
Which VCs invest in companies like NephroGenex?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at NephroGenex's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like NephroGenex? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.